CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature - PubMed (original) (raw)
CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature
Anjali P Kusumbe et al. Stem Cells. 2009 Mar.
Abstract
Recruitment and localization of endothelial precursors within tumors is a potential area for the development of therapeutics, because their functional contribution to tumor vasculature is realized to be important for cancer cell survival. However, the exact nature of the recruited cell type and cellular events orchestrating the entire phenomenon remains obscure. We report that human ovarian cancer is frequently associated with cells expressing the stem cell surface marker CD133. We further show that these CD133-expressing cells are nontumorigenic in nature, and they augment tumor development through their vasculogenic potential. This cell population is attracted by cancer stem cells (CSCs) and retains a direct physical association within the CSC-derived spheroids. Our study further delineates the contribution of these vasculogenic CD133(+) stem cells, termed by us as endothelial stem cells (EnSCs) to the developing tumor vasculature during disease progression. In support of their being stem cells, the EnSCs have a capability of establishing an entire endothelial cell hierarchy. We conclude that such EnSCs play a crucial role in ensuring the development of long-term tumor vasculature to complement CSC-driven tumor development and disease progression.
Similar articles
- DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
Kim KH, Kang YJ, Jo JO, Ock MS, Moon SH, Suh DS, Yoon MS, Park ES, Jeong N, Eo WK, Kim HY, Cha HJ. Kim KH, et al. Biochem Biophys Res Commun. 2014 May 2;447(2):315-22. doi: 10.1016/j.bbrc.2014.03.144. Epub 2014 Apr 13. Biochem Biophys Res Commun. 2014. PMID: 24727449 - Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ. Silva IA, et al. Cancer Res. 2011 Jun 1;71(11):3991-4001. doi: 10.1158/0008-5472.CAN-10-3175. Epub 2011 Apr 15. Cancer Res. 2011. PMID: 21498635 Free PMC article. - [Isolation and identification of cancer stem cells from primary human ovarian cancer tissues].
Lin S, Long HX, Xiang T, Zhu B, Xie RK. Lin S, et al. Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):896-9. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22340097 Chinese. - How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX, Liu BL, Zhang X. Cheng JX, et al. Cancer Treat Rev. 2009 Aug;35(5):403-8. doi: 10.1016/j.ctrv.2009.03.002. Epub 2009 Apr 14. Cancer Treat Rev. 2009. PMID: 19369008 Review. - CD133: molecule of the moment.
Mizrak D, Brittan M, Alison M. Mizrak D, et al. J Pathol. 2008 Jan;214(1):3-9. doi: 10.1002/path.2283. J Pathol. 2008. PMID: 18067118 Review.
Cited by
- Advances in complex multiparameter flow cytometry technology: Applications in stem cell research.
Preffer F, Dombkowski D. Preffer F, et al. Cytometry B Clin Cytom. 2009 Sep;76(5):295-314. doi: 10.1002/cyto.b.20480. Cytometry B Clin Cytom. 2009. PMID: 19492350 Free PMC article. Review. - The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.
Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM, Suo Z. Liang D, et al. BMC Cancer. 2012 May 29;12:201. doi: 10.1186/1471-2407-12-201. BMC Cancer. 2012. PMID: 22642602 Free PMC article. - Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas.
Shoreibah MG, Jackson CL, Price PW, Meagher R, Godwin AK, Cai Q, Gildersleeve JC. Shoreibah MG, et al. Stem Cells Dev. 2011 Mar;20(3):515-25. doi: 10.1089/scd.2010.0172. Epub 2010 Nov 8. Stem Cells Dev. 2011. PMID: 20887211 Free PMC article. - Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.
Xiang T, Long H, He L, Han X, Lin K, Liang Z, Zhuo W, Xie R, Zhu B. Xiang T, et al. Oncogene. 2015 Jan 8;34(2):165-76. doi: 10.1038/onc.2013.537. Epub 2013 Dec 23. Oncogene. 2015. PMID: 24362529 - Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor.
Liu KC, Yo YT, Huang RL, Wang YC, Liao YP, Huang TS, Chao TK, Lin CK, Weng SJ, Ma KH, Chang CC, Yu MH, Lai HC. Liu KC, et al. Oncotarget. 2013 Dec;4(12):2366-82. doi: 10.18632/oncotarget.1424. Oncotarget. 2013. PMID: 24280306 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials